Patient P-02029
Therapy response
Stable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
52%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S18
- Day 21 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 21.
Primary contributors, last 14 days
- Toxicity-14
- Inflammatory activity-8
- Treatment adherence+8
- Nutritional resilience-6
- GI instability-2
What helped?
No interventions yet.
LIFE OS recommendation
GI Support Protocol GI-04
65%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 88% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 29/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 59
- WearableHRV 32 ms, trending down
- Autonomic recovery ↑45
- WearableResting HR 79 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 46
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 2.6 · butyrate capacity 29/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 29 ms
- Sleep
- 6.3 h
- Steps
- 7,617
- Resting HR
- 79 bpm
Daily log: GI score 59, nutritional resilience 33, adherence 72.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02631 | 51% | S17 | — | — | 58 |
| P-02084 | 50% | S11 | GI-04 | no change | 58 |
| P-02025 | 48% | S15 | CR-01 | improved | 61 |
| P-02054 | 47% | S01 | CR-01 | improved | 57 |
| P-02034 | 46% | S18 | — | — | 61 |
| P-02151 | 45% | S04 | CR-01 | improved | 49 |
| P-02521 | 45% | S14 | — | — | 53 |
| P-02205 | 44% | S20 | — | — | 57 |
| P-02472 | 44% | S14 | — | — | 60 |
| P-02591 | 44% | S13 | — | — | 68 |
| P-02111 | 43% | S20 | — | — | 51 |
| P-02136 | 43% | S10 | — | — | 63 |